TY - JOUR
T1 - Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities
T2 - a cross-sectional multicenter study from Madinah
AU - Housawi, Abdulrahman A.
AU - Qazi, Shazada Junaid S.
AU - Jan, Abdulhalem A.
AU - Osman, Rashid A.
AU - Alshamrani, Mashil M.
AU - AlFaadhel, Talal A.
AU - AlHejaili, Fayez F.
AU - Al-Tawfiq, Jaffar A.
AU - Wafa, Ahmed A.
AU - Hamza, Abdulmageed E.
AU - Hassan, Moustafa A.
AU - Alharbi, Suliman A.
AU - Albasheer, Hamza
AU - Almohmmdi, Majed M.
AU - Alsisi, Salem A.
AU - Mankowski, Michal
AU - Van de Klundert, Joris
AU - Alhelal, Amal M.
AU - Sala, Fatima H.
AU - Kheyami, Ali
AU - Alhomayeed, Bader A.
N1 - Publisher Copyright:
Copyright: Copyright © 2022, Annals of Saudi Medicine, Saudi Arabia.
PY - 2022/7
Y1 - 2022/7
N2 - BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immuno-globulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. CONCLUSION: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others.
AB - BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immuno-globulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. CONCLUSION: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others.
UR - https://www.scopus.com/pages/publications/85135598662
U2 - 10.5144/0256-4947.2022.229
DO - 10.5144/0256-4947.2022.229
M3 - Article
C2 - 35933611
AN - SCOPUS:85135598662
SN - 0256-4947
VL - 42
SP - 229
EP - 235
JO - Annals of Saudi Medicine
JF - Annals of Saudi Medicine
IS - 4
ER -